GlycoMimetics Inc (GLYC)
1.74
-0.12
(-6.20%)
USD |
NASDAQ |
Apr 25, 13:32
GlycoMimetics Cash and Short Term Investments (Quarterly): 41.79M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 41.79M |
| September 30, 2023 | 49.41M |
| June 30, 2023 | 58.04M |
| March 31, 2023 | 65.00M |
| December 31, 2022 | 47.87M |
| September 30, 2022 | 51.62M |
| June 30, 2022 | 60.24M |
| March 31, 2022 | 76.52M |
| December 31, 2021 | 90.25M |
| September 30, 2021 | 101.92M |
| June 30, 2021 | 118.85M |
| March 31, 2021 | 132.47M |
| December 31, 2020 | 137.04M |
| September 30, 2020 | 142.87M |
| June 30, 2020 | 149.84M |
| March 31, 2020 | 154.82M |
| December 31, 2019 | 158.20M |
| September 30, 2019 | 170.89M |
| June 30, 2019 | 184.17M |
| March 31, 2019 | 195.56M |
| December 31, 2018 | 209.92M |
| September 30, 2018 | 219.83M |
| Date | Value |
|---|---|
| June 30, 2018 | 229.43M |
| March 31, 2018 | 242.63M |
| December 31, 2017 | 123.92M |
| September 30, 2017 | 112.87M |
| June 30, 2017 | 119.15M |
| March 31, 2017 | 34.59M |
| December 31, 2016 | 40.04M |
| September 30, 2016 | 45.28M |
| June 30, 2016 | 53.09M |
| March 31, 2016 | 38.83M |
| December 31, 2015 | 46.80M |
| September 30, 2015 | 53.76M |
| June 30, 2015 | 40.23M |
| March 31, 2015 | 46.57M |
| December 31, 2014 | 55.20M |
| September 30, 2014 | 61.36M |
| June 30, 2014 | 66.22M |
| March 31, 2014 | 56.97M |
| December 31, 2013 | 2.311M |
| September 30, 2013 | 7.690M |
| June 30, 2013 | 10.78M |
| December 31, 2012 | 17.37M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
41.79M
Minimum
Dec 2023
184.17M
Maximum
Jun 2019
104.83M
Average
101.92M
Median
Sep 2021
Cash and Short Term Investments (Quarterly) Benchmarks
| Altimmune Inc | 197.82M |
| Cellectar Biosciences Inc | 9.565M |
| PDS Biotechnology Corp | 56.56M |
| Syros Pharmaceuticals Inc | 139.53M |
| Precision BioSciences Inc | 116.68M |